Endometrial cancer (EC) has an increasing incidence worldwide, with lymph node metastases as the main prognostic factor. Systemic lymphadenectomy is connected with elevated morbidity. Sentinel lymph ...

Revance Therapeutics, Inc. (RVNC) today announced that new data on DAXXIFY® will be presented at the annual meeting of Association of Academic Physiatrists (AAP), taking place in Anaheim, California, ...

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for DAXXIFY® ...

Revance Therapeutics, Inc, announced the commercial launch of Daxxify (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia, providing patients and physicians with a ...